DOCSLIB.ORG

Antidepressant Treatment of Depression in Schizophrenia: a Systematic Review and Meta-Analysis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Antidepressant Treatment of Depression in Schizophrenia: a Systematic Review and Meta-Analysis Antidepressant Treatment of Depression in Schizophrenia: A Systematic Review and Meta-Analysis Dr Rachel Upthegrove, Senior Clinical Lecturer, Department of Psychiatry, College of Medical and Dental Sciences. Angharad Gregory, Medical Student University of Birmingham Keywords: Schizophrenia, Psychosis, Depression, Antidepressant, Quality of life and Suicide. Background Co-morbid depression in schizophrenia is common, with prevalence rates reported from 25%(1) to 83%(2). The variation in prevalence is partly due to the challenge in distinguishing symptoms of a mood disorder from core negative symptoms in schizophrenia, for example, blunted affect and difficulty expressing emotion. The discrepancy is further attributed to insufficiency of current classification systems in diagnosing concurrent depression in schizophrenia. However, following results of recent epidemiological studies, the overall consensus is that depressive syndromes are present in 50% of individuals with schizophrenia.(3) Depressive symptoms in schizophrenia can occur in all phases of the illness and cause significant distress. The consequences of depression in schizophrenia are serious and include more frequent relapses(4), increased duration of illness (5) and high rate of substance abuse(6). Suicide is 13 times more likely in people with schizophrenia than in the general population(7). It has also been found that of those that commit suicide, 57% had also been depressed(8). In order to improve quality of life and reduce rates of suicide, effective treatment of depressive symptoms is needed. The optimal treatment approach for depression in schizophrenia is disputed. Guidelines on treatment recommendations from National Institute of Clinical Excellence (NICE)(9) and British Association for Psychopharmacology(10) are brief and without conclusion. NICE recommends Cognitive Behavioural Therapy to all people with schizophrenia or related psychoses but not specifically for concurrent depression(9). The literature on psychological intervention is modest. Most studies on psychological treatments have not investigated depression as a primary outcome or with well-validated scales(11). In terms of pharmacological therapy, in the early 2000’s there was hope that some of the newer atypical antipsychotics may be effective in ameliorating co-morbid depressive symptomatology(12, 13), particularly olanzapine(14, 15) and quetiapine(16, 17). However, a Cochrane review in 2008 (18) found no evidence to support atypical antipsychotics are any better than typical antipsychotics for treating depression in people with schizophrenia. The review was based on three extremely small, poorly reported, short studies, vulnerable to bias. The authors suggested practice at that time should be guided by evidence other than that derived from randomised trials.(18) The potential benefit of antidepressants for co-morbid depression has not received the attention it warrants.(19) Early studies in the 90’s investigating the use of tricyclic antidepressants, mainly imipramine, showed some significance in treating co-morbid depressive features (20, 21). However, there has since been minimal advancement. Whitehead et al (5) conducted a systematic review in 2002 identifying just 11 appropriate trials. The majority used tricyclic antidepressants, with one study investigating a selective serotonin reuptake inhibitor.(22) In general, studies were small and of poor quality, with multiple methodological flaws including small sample size, inadequate description of allocation concealment, absent power calculations and multiple trials did not use an intention-to-treat analysis. (5) Although a subgroup analysis indicated some clinical benefit of antidepressants, drawing results from a small number of small trials is unreliable. Furthermore, it was impossible to investigate the likelihood of publication bias as another consequence of the limited trials in the review. To conclude, Whitehead (5) reported although the evidence suggests some clinical benefit of co-prescribing antidepressants in schizophrenia a fairer conclusion would be evidence at that time remains “unproven”. The review is now out of date and the need for a definitive answer regarding the use of antidepressant therapy persists. A substantial body of evidence suggests the use of antidepressant medication in schizophrenia is increasing.(23) It has been reported, antidepressants are prescribed for 11 to 43% of patients with schizophrenia (4). Notably, alongside depressive symptoms, they are also used to treat anxiety and negative symptoms. However, polypharmacy increases drug interactions and side effects. A number of case reports have shown concurrent use of selective serotonin reuptake inhibitors and new antipsychotics is associated with arrhythmias, prolonged QTc interval on electrocardiogram and orthostatic hypotension in patients with otherwise normal cardiovascular systems (24). Therefore, it is essential to determine if the use of antidepressants for depression is therapeutic or futile in order to prevent unnecessary harm. In summary, the evidence base for the regular co-pharmacy of antidepressants alongside antipsychotics in clinical practice is weak. Considering how frequently depression occurs as a discrete syndrome in schizophrenia, as well as being a significant mediator of disability and potentially leading to suicide, research into the role of antidepressant therapy is essential to establish adequately informed guidelines.(3) Aim The aim of the study is to conduct a systematic review and meta-analysis of the use of antidepressants as an adjunct to antipsychotic medication to treat depression in people with schizophrenia. 1 Objectives To synthesise evidence of the effectiveness of antidepressants for treatment of depression in people with schizophrenia To estimate the aggregate effectiveness of antidepressants for treatment of depression in people with schizophrenia Setting This project is a systematic review therefore will be using published data, not specific to any location. Methods/Design A systematic review and meta-analysis will be conducted with outcomes reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (25). A PRISMA flow diagram will create a graphical representation of citations reviewed in the course of the systematic review (see Appendix 2). Data will be extrapolated and assessed using Cochrane tools for data extraction (26) and risk of bias (27), respectively. Selection Criteria (See Appendix 3 for inclusion criteria table/screening tool) 1. Types of Participants Participants will include any individual aged 18 years or older with schizophrenia or related psychosis; including schizoaffective disorder and psychotic disorder not otherwise specified (as diagnosed using International Classification Diseases-10) with a depressive episode (as assessed using a standardised rating scale or clinical interview). Studies including participants under 18 years old or with a primary diagnosis of organic brain disorder or bipolar disorder will be excluded from the systematic review. This is justified on the basis that depression experienced in these disorders would have a very different aetiology and would be managed differently to the focus of this review. 2. Types of Intervention Interventions used in included trials will take an antidepressant versus usual care or placebo approach. Any class of antidepressant: tricyclic antidepressant; monoamine oxidase inhibitor; selective serotonin reuptake inhibitor or other type will be valid as per those published in the BNF (section 4.3).(28) Agents with only theoretical antidepressant properties never approved in any country for depression will be excluded. It is anticipated that all people in the study will be receiving antipsychotic medication and possibly an anticholinergic. All medications participants receive throughout the trial duration should be charted, monitored and reported. 3. Types of Outcome Primary Outcome: The primary outcome will be recovery from depression using dichotomous outcomes (depressed/ not depressed) provided by the authors. Continuous outcomes, showing change on standardised scales will also be included. Secondary Outcomes: These will include positive and negative symptoms of schizophrenia and quality of life, using any psychometrically validated scale both self-reported and clinician administered. Timing of Outcome Measures: It is anticipated the time points of measuring outcomes will vary. It may be necessary to group outcome measures into short-term, medium-term and long-term outcomes. For example, as guided by results of Whitehead et al (5), <6 weeks, <12 weeks and >12 weeks, respectively. 4. Types of Studies All appropriate randomised controlled trials or quasi-experimental studies will be included. Observational or qualitative studies will not be included. Search Methods and Identification of Studies The search strategy aims to find both published and unpublished studies to minimise chance of publication bias. 1. Electronic searches The following electronic bibliographic databases will be searched: The Cochrane Central Register of Controlled Trials; MEDLINE (1948 to present); EMBASE (1980 to present); CINAHL (1982 to present); PsycINFO (1967 to present) and Web of Science (1990 to present). The final search update will be 29th February 2015. (See Appendix 1 for MEDLINE search). The following limits will be set: 1. Randomised controlled trials (RCTs) or quasi-experimental studies, 2. English language
Load more

Recommended publications
  • Still the Leading Antidepressant After 40
    BRITISH JOURNAL OF PSYCHIATRY "2001), 178, 129^144 REVIEW ARTICLE Amitriptyline vv.therest:stilltheleading METHOD Inclusion criteria antidepressant after 40 years of randomised All RCTs comparing amitriptyline with any y other tricyclic,heterocyclic or SSRI were in- controlled trials cluded. Crossover studies were excluded. Studies adopting any criteria to define CORRADO BARBUI and MATTHEW HOTOPF patients suffering from depression were included; a concurrent diagnosis of another psychiatric disorder was not considered an exclusion criterion. Trials in patients with depression with a concomitant medical ill- Background Tricyclic antidepressants Amitriptyline is one of the first `reference' ness were not included in this review. have similar efficacy and slightly lower tricyclic antidepressants TCAs). Over the past 40 years a number of newer tricyclics, tolerability than selective serotonin Search strategy heterocyclics and selective serotonin re- Relevant studies were located by searching reuptakeinhibitorsreuptake inhibitors SSRIs).However, uptake inhibitors SSRIs) have been intro- the Cochrane Collaboration Depression, there are no systematic reviews assessing duced Garattini et aletal,1998). Despite Anxiety and Neurosis Controlled Trials several large systematic reviews comparing amitriptyline, the reference tricyclic drug, Register CCDANCTR). This specialised tricyclics and SSRIs there is no clear agree- vv. other tricyclics and SSRIs directly. register is regularly updated by electronic ment over first-line treatment of depression Medline,Embase,PsycINFO,LILACS, SongSong et aletal,1993; Anderson & Tomenson, Aims ToreviewTo review the tolerability and Psyndex,CINAHL,SIGLE) and non-electro- 1995; Montgomery & Kasper,1995; efficacy of amitriptyline inthe nicnicliterature searches. The register was HotopfHotopf et aletal,1996; Canadian Coordinating management of depression. searched using the following terms: Office for Health Technology Assessment, AMITRIPTYLIN**AMITRIPTYLIN oror AMITRILAMITRIL oror ELA-ELA- 19971997aa).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0190743 A1 Bain Et Al
    US 2012O190743A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0190743 A1 Bain et al. (43) Pub. Date: Jul. 26, 2012 (54) COMPOUNDS FOR TREATING DISORDERS Publication Classification OR DISEASES ASSOCATED WITH (51) Int. Cl NEUROKININ 2 RECEPTORACTIVITY A6II 3L/23 (2006.01) (75) Inventors: Jerald Bain, Toronto (CA); Joel CD7C 69/30 (2006.01) Sadavoy, Toronto (CA); Hao Chen, 39t. ii; C Columbia, MD (US); Xiaoyu Shen, ( .01) Columbia, MD (US) A6IPI/00 (2006.01) s A6IP 29/00 (2006.01) (73) Assignee: UNITED PARAGON A6IP II/00 (2006.01) ASSOCIATES INC., Guelph, ON A6IPI3/10 (2006.01) (CA) A6IP 5/00 (2006.01) A6IP 25/00 (2006.01) (21) Appl. No.: 13/394,067 A6IP 25/30 (2006.01) A6IP5/00 (2006.01) (22) PCT Filed: Sep. 7, 2010 A6IP3/00 (2006.01) CI2N 5/071 (2010.01) (86). PCT No.: PCT/US 10/48OO6 CD7C 69/33 (2006.01) S371 (c)(1) (52) U.S. Cl. .......................... 514/552; 554/227; 435/375 (2), (4) Date: Apr. 12, 2012 (57) ABSTRACT Related U.S. Application Data Compounds, pharmaceutical compositions and methods of (60) Provisional application No. 61/240,014, filed on Sep. treating a disorder or disease associated with neurokinin 2 4, 2009. (NK) receptor activity. Patent Application Publication Jul. 26, 2012 Sheet 1 of 12 US 2012/O190743 A1 LU 1750 15OO 1250 OOO 750 500 250 O O 20 3O 40 min SampleName: EM2OO617 Patent Application Publication Jul. 26, 2012 Sheet 2 of 12 US 2012/O190743 A1 kixto CFUgan <tro CFUgan FIG.2 Patent Application Publication Jul.
    [Show full text]
  • Still the Leading Antidepressant After 40 Years of Randomised Controlle
    BRITISH JOURNAL OF PSYCHIATRY "2001), 178, 129^144 REVIEW ARTICLE Amitriptyline vv.therest:stilltheleading METHOD Inclusion criteria antidepressant after 40 years of randomised All RCTs comparing amitriptyline with any y other tricyclic,heterocyclic or SSRI were in- controlled trials cluded. Crossover studies were excluded. Studies adopting any criteria to define CORRADO BARBUI and MATTHEW HOTOPF patients suffering from depression were included; a concurrent diagnosis of another psychiatric disorder was not considered an exclusion criterion. Trials in patients with depression with a concomitant medical ill- Background Tricyclic antidepressants Amitriptyline is one of the first `reference' ness were not included in this review. have similar efficacy and slightly lower tricyclic antidepressants TCAs). Over the past 40 years a number of newer tricyclics, tolerability than selective serotonin Search strategy heterocyclics and selective serotonin re- Relevant studies were located by searching reuptakeinhibitorsreuptake inhibitors SSRIs).However, uptake inhibitors SSRIs) have been intro- the Cochrane Collaboration Depression, there are no systematic reviews assessing duced Garattini et aletal,1998). Despite Anxiety and Neurosis Controlled Trials several large systematic reviews comparing amitriptyline, the reference tricyclic drug, Register CCDANCTR). This specialised tricyclics and SSRIs there is no clear agree- vv. other tricyclics and SSRIs directly. register is regularly updated by electronic ment over first-line treatment of depression Medline,Embase,PsycINFO,LILACS, SongSong et aletal,1993; Anderson & Tomenson, Aims ToreviewTo review the tolerability and Psyndex,CINAHL,SIGLE) and non-electro- 1995; Montgomery & Kasper,1995; efficacy of amitriptyline inthe nicnicliterature searches. The register was HotopfHotopf et aletal,1996; Canadian Coordinating management of depression. searched using the following terms: Office for Health Technology Assessment, AMITRIPTYLIN**AMITRIPTYLIN oror AMITRILAMITRIL oror ELA-ELA- 19971997aa).
    [Show full text]
  • British Brand Name
    Standardisation framework for the Maudsley staging method for treatment resistance in depression Article (Supplemental Material) Fekadu, Abebaw, Donocik, Jacek G and Cleare, Anthony J (2018) Standardisation framework for the Maudsley staging method for treatment resistance in depression. BMC Psychiatry, 18 (100). pp. 1-13. ISSN 1471-244X This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/75748/ This document is made available in accordance with publisher policies and may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher’s version. Please see the URL above for details on accessing the published version. Copyright and reuse: Sussex Research Online is a digital repository of the research output of the University. Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable, the material made available in SRO has been checked for eligibility before being made available. Copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way. http://sro.sussex.ac.uk
    [Show full text]
  • Tcas Versus Placebo - New Studies in the Guideline Update
    TCAs versus placebo - new studies in the guideline update Comparisons Included in this Clinical Question Amitriptyline vs placebo Clomipramine vs placebo Dosulepin (dothiepin) vs placebo AMSTERDAM2003A LARSEN1989 FERGUSON1994B BAKISH1992B PECKNOLD1976B ITIL1993 BAKISH1992C RAMPELLO1991 MINDHAM1991 BREMNER1995 THOMPSON2001B CLAGHORN1983 CLAGHORN1983B FEIGHNER1979 GELENBERG1990 GEORGOTAS1982A GOLDBERG1980 HICKS1988 HOLLYMAN1988 HORMAZABAL1985 HOSCHL1989 KLIESER1988 LAAKMAN1995 LAPIERRE1991 LYDIARD1997 MYNORSWALLIS1995 MYNORSWALLIS1997 REIMHERR1990 RICKELS1982D RICKELS1985 RICKELS1991 ROFFMAN1982 ROWAN1982 SMITH1990 SPRING1992 STASSEN1993 WILCOX1994 16 Imipramine vs placebo BARGESCHAAPVELD2002 BEASLEY1991B BOYER1996A BYERLEY1988 CASSANO1986 CASSANO1996 CLAGHORN1996A COHN1984 COHN1985 COHN1990A COHN1992 COHN1996 DOMINGUEZ1981 DOMINGUEZ1985 DUNBAR1991 ELKIN1989 ENTSUAH1994 ESCOBAR1980 FABRE1980 FABRE1992 FABRE1996 FEIGER1996A FEIGHNER1980 FEIGHNER1982 FEIGHNER1983A FEIGHNER1983B FEIGHNER1989 FEIGHNER1989A FEIGHNER1989B FEIGHNER1989C FEIGHNER1992B FEIGHNER1993 FONTAINE1994 GELENBERG2002 GERNER1980B HAYES1983 ITIL1983A KASPER1995B KELLAMS1979 LAIRD1993 LAPIERRE1987 LECRUBIER1997B LIPMAN1986 LYDIARD1989 MARCH1990 17 MARKOWITZ1985 MENDELS1986 MERIDETH1983 Nortriptyline vs placebo NANDI1976 GEORGOTAS1986A NORTON1984 KATZ1990 PEDERSEN2002 NAIR1995 PESELOW1989 WHITE1984A PESELOW1989B PHILIPP1999 QUITKIN1989 RICKELS1981 RICKELS1982A RICKELS1987 SCHWEIZER1994 SCHWEIZER1998 SHRIVASTAVA1992 SILVERSTONE1994 SMALL1981 UCHA1990 VERSIANI1989 VERSIANI1990
    [Show full text]
  • 1 Supplemental Figure 1: Illustration of Time-Varying
    Supplemental Material Table of Contents Supplemental Table 1: List of classes and medications. Supplemental Table 2: Association between benzodiazepines and mortality in patients initiating hemodialysis (n=69,368) between 2013‐2014 stratified by age, sex, race, and opioid co‐dispensing. Supplemental Figure 1: Illustration of time‐varying exposure to benzodiazepine or opioid claims for one person. Several sensitivity analyses were performed wherein person‐day exposure was extended to +7 days, +14 days, and +28 days beyond the outlined periods above. 1 Supplemental Table 1: List of classes and medications. Class Medications Short‐acting benzodiazepines Alprazolam, estazolam, lorazepam, midazolam, oxazepam, temazepam, and triazolam Long‐acting benzodiazepines chlordiazepoxide, clobazam, clonazepam, clorazepate, diazepam, flurazepam Opioids alfentanil, buprenorphine, butorphanol, codeine, dihydrocodeine, fentanyl, hydrocodone, hydromorphine, meperidine, methadone, morphine, nalbuphine, nucynta, oxycodone, oxymorphone, pentazocine, propoxyphene, remifentanil, sufentanil, tapentadol, talwin, tramadol, carfentanil, pethidine, and etorphine Antidepressants citalopram, escitalopram, fluoxetine, fluvozamine, paroxetine, sertraline; desvenlafaxine, duloxetine, levomilnacipran, milnacipran, venlafaxine; vilazodone, vortioxetine; nefazodone, trazodone; atomoxetine, reboxetine, teniloxazine, viloxazine; bupropion; amitriptyline, amitriptylinoxide, clomipramine, desipramine, dibenzepin, dimetacrine, dosulepin, doxepin, imipramine, lofepramine, melitracen,
    [Show full text]
  • Resume of Scientific Contributions to Psychopharmacology And
    RESUME OF SCIENTIFIC CONTRIBUTIONS TO PSYCHOPHARMACOLOGY AND BIOLOGICAL PSYCHIATRY While Fridolin Sulser was a visiting scientist from Switzerland in the Laboratory of Chemical Pharmacology at the National Institutes of Health in Bethesda, Maryland, he and B.B. Brodie utilized the reserpine-like syndrome as a "model depression" and in due course discovered the secondary amine desmethyl-imipramine (DM1) formed in vivo by oxidative N-demethylation of imipramine (1,2).DMI turned out to be the first selective inhibitor of the high affinity uptake of norepinephrine and triggered the development of many secondary amines of tricyclic antidepressants as therapeutic agents (e.g. desipramine, nortriptyline, protriptyline maprotiline, oxaprotiline, and more recently reboxetine). These drugs provided more selective pharmacologic tools to dissect the role of central noradrenergic mechanisms (3). During the early 1970s, Fridolin Sulser and his associates discovered that treatment with antidepressants on a clinically relevant time basis (including tricyclics, 4- Fridolin Sulser, M.D. Curriculum Vitae MAO inhibitors, some atypical antidepressants and electroconvulsive treatment) reduces selectively the responsiveness of the norepinephrine (NE) beta adrenoceptor coupled adenylate cyclase system in limbic and cortical structures of the rat brain (4,5). This deamplification of the central beta adrenoceptor system is often linked to a down- regulation of the Brnax value of beta adrenoceptors, without changes in the KD. These findings shifted the research emphasis on the mode of action of antidepressant treatments and on the pathophysiology of affective disorders from acute presynaptic to delayed post-synaptic receptor - second messenger mediated events and emphasized the role of adaptive processes at the level of signal transduction and opened the gateway for subsequent studies on changes of programs of gene expression.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 100 Ol
    US 2002O102215A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 Klaveness et al. (43) Pub. Date: Aug. 1, 2002 (54) DIAGNOSTIC/THERAPEUTICAGENTS (60) Provisional application No. 60/049.264, filed on Jun. 6, 1997. Provisional application No. 60/049,265, filed (75) Inventors: Jo Klaveness, Oslo (NO); Pal on Jun. 6, 1997. Provisional application No. 60/049, Rongved, Oslo (NO); Anders Hogset, 268, filed on Jun. 7, 1997. Oslo (NO); Helge Tolleshaug, Oslo (NO); Anne Naevestad, Oslo (NO); (30) Foreign Application Priority Data Halldis Hellebust, Oslo (NO); Lars Hoff, Oslo (NO); Alan Cuthbertson, Oct. 28, 1996 (GB)......................................... 9622.366.4 Oslo (NO); Dagfinn Lovhaug, Oslo Oct. 28, 1996 (GB). ... 96223672 (NO); Magne Solbakken, Oslo (NO) Oct. 28, 1996 (GB). 9622368.0 Jan. 15, 1997 (GB). ... 97OO699.3 Correspondence Address: Apr. 24, 1997 (GB). ... 9708265.5 BACON & THOMAS, PLLC Jun. 6, 1997 (GB). ... 9711842.6 4th Floor Jun. 6, 1997 (GB)......................................... 97.11846.7 625 Slaters Lane Alexandria, VA 22314-1176 (US) Publication Classification (73) Assignee: NYCOMED IMAGING AS (51) Int. Cl." .......................... A61K 49/00; A61K 48/00 (52) U.S. Cl. ............................................. 424/9.52; 514/44 (21) Appl. No.: 09/765,614 (22) Filed: Jan. 22, 2001 (57) ABSTRACT Related U.S. Application Data Targetable diagnostic and/or therapeutically active agents, (63) Continuation of application No. 08/960,054, filed on e.g. ultrasound contrast agents, having reporters comprising Oct. 29, 1997, now patented, which is a continuation gas-filled microbubbles stabilized by monolayers of film in-part of application No. 08/958,993, filed on Oct.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Incidence of and Risk Factors for Chronic Opioid Use Among Opioid-Naive Patients in the Postoperative Period
    Supplementary Online Content Sun EC, Darnall BD, Baker LC, Mackey S. Incidence of and risk factors for chronic opioid use among opioid-naïve patients in the postoperative period. JAMA Intern Med. Published online July 11, 2016. doi:10.1001/jamainternmed.2016.3298. eTable 1. List of CPT Codes eFigure. Sample Construction Flow Chart eTable 2. List of Drug Classes eTable 3. List of Medical Comorbidities and ICD-9 Codes eTable 4. Sample Summary Characteristics, by procedure eTable 5. Risk Factors for Chronic Opioid Use Following Surgery Among Opioid Naïve Patients This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/29/2021 eTable 1. List of CPT codes CPT Codes Total Knee Arthroplasty1 27447 Total Hip Arthroplasty1 27130 Laparoscopic Cholecystectomy2 47562, 47563, 47564 Open Cholecystectomy3 47600, 47605, 47610 Laparoscopic Appendectomy4 44970, 44979 Open Appendectomy5 44950, 44960 Cesarean Section6 59510, 59514, 59515 FESS7 31237, 31240, 31254, 31255, 31256, 31267, 31276, 31287, 31288 Cataract Surgery8 66982, 66983, 66984 TURP9 52601, 52612, 52614 Simple Mastectomy10‐12 19301, 19302, 19303, 19180 © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/29/2021 eFigure. Sample Construction Flow Chart © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/29/2021 eTable 2.
    [Show full text]
  • Is Hyperbaric Oxygen Therapy an Effective Treatment for Autism
    Running Head: VETERANS, ANTIDEPRESSANTS, AND SUICIDE 1 Veterans, Antidepressants, and Suicide: A Systematic Review of Adverse Events Daniel J. Dunleavy1 Jeffrey R. Lacasse2 Shannon Hughes3 Cassandra Olson4 MaKenna Woods2 1 Florida State University, Center for Translational Behavioral Science 2 Florida State University, College of Social Work 3 Colorado State University, College of Health and Human Sciences 4 Florida State University, College of Health and Human Sciences Author Note Daniel J. Dunleavy https://orcid.org/0000-0002-3597-7714 The authors have no conflicts of interest to disclose. Correspondence concerning this article should be addressed to Daniel J. Dunleavy, Center for Translational Behavioral Science, Florida State University, 2010 Levy Ave, Building B, Suite B0266, Tallahassee, FL 32310. Email: [email protected] VETERANS, ANTIDEPRESSANTS, AND SUICIDE 2 Abstract Background: Military veterans represent a disproportionate number of suicides that occur in the U.S. Antidepressants have been associated with increased risk of suicidal thoughts/behaviors and completed suicide. Given the high number of psychotropic medications prescribed to the veteran population, it is salient that any relationship between veteran suicide and antidepressants be explored. Method: A preregistered systematic review was conducted of empirical studies from 1988-2018. Studies were identified through electronic bibliographic databases. Results: A total of 25 studies met eligibility criteria. Studies reviewed only minimally explored adverse effects of antidepressants.
    [Show full text]
  • Antidepressants for Neuropathic Pain (Review)
    Antidepressants for neuropathic pain (Review) Saarto T, Wiffen PJ This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2007, Issue 4 http://www.thecochranelibrary.com Antidepressants for neuropathic pain (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 2 OBJECTIVES ..................................... 3 METHODS ...................................... 3 RESULTS....................................... 5 DISCUSSION ..................................... 11 AUTHORS’CONCLUSIONS . 12 ACKNOWLEDGEMENTS . 12 REFERENCES ..................................... 13 CHARACTERISTICSOFSTUDIES . 19 DATAANDANALYSES. 65 Analysis 1.1. Comparison 1 Global improvement - number of patients with moderate pain relief or better, Outcome 1 Amitriptylineversusplacebo. 67 Analysis 1.2. Comparison 1 Global improvement - number of patients with moderate pain relief or better, Outcome 2 Desipraminevsplacebo. 68 Analysis 1.3. Comparison 1 Global improvement - number of patients with moderate pain relief or better, Outcome 3 Imipraminevsplacebo. 68 Analysis 1.4. Comparison 1 Global improvement - number of patients with moderate pain relief or better, Outcome 4 Other antidepressants vs placebo. ..... 69 Analysis 1.5. Comparison 1 Global improvement - number of patients
    [Show full text]